Who is Maria in the Ozempic commercial?
Unpacking the story behind the testimonial face of the “My Ozempic Era” campaign
(By Carmichael Phillip)
In recent years, the pharmaceutical and marketing world has seen a surge in direct-to-consumer campaigns that center the voices of patients themselves. Rather than relying solely on abstract claims or statistics, companies increasingly use “real people” (or real-looking spokespeople) sharing personal stories to humanize their products. One such campaign is Novo Nordisk’s “My Ozempic® Era”, and one of its prominent faces is Maria.
You may have seen Maria in the Ozempic commercial, testifying to her journey managing type 2 diabetes. But who is she, really? What is the story behind “Maria” in that TV spot? In this article, we’ll dig into her background, her role in Novo Nordisk’s marketing, and what her portrayal means for audiences.
Who is Maria? The background behind the face
In the Ozempic campaign, Maria is introduced as an individual living with type 2 diabetes who has taken steps to manage her condition with diet, exercise, and treatment (specifically, Ozempic).
The official Ozempic “Real Stories” page describes Maria as a proud entrepreneur and salon owner who works to balance her health decisions and responsibilities.
Maria speaks in the ad about lowering her A1C, losing some weight (or managing her weight), and maintaining confidence in her choices.
Through this, she fits the role of a “patient spokesperson” — someone put before the camera to represent how the drug may benefit real people.
It’s worth noting: Maria is not just a random name. Novo Nordisk has identified her publicly as one of three “stories” they are elevating in this campaign, alongside others like Michael Trotter Jr. and chef Franklin Becker.
In press materials, she is described as a salon owner and entrepreneur.
So she is more than a character — she is part of the real voices (or carefully curated voices) used to sell a medical product.
Maria’s role in the “My Ozempic Era” campaign
Maria is part of Novo Nordisk’s broader “My Ozempic Era” promotional initiative, which launched in early 2025. This campaign highlights three people living with type 2 diabetes who use Ozempic — Maria is one of them.
The goal: to celebrate “stories of inspirational Ozempic patients” and to encourage others with type 2 diabetes to consider how treatment can be part of their journey.
In press releases, Novo states that Maria’s story is meant to show how someone can manage diabetes while maintaining life roles — as entrepreneur, parent, community member — not letting the disease define them.
She is presented as authentic, relatable, and aspirational. The fact that she is called out by name lends credibility (or at least the appearance of it) to the campaign.
Her inclusion alongside well-known names (Michael Trotter Jr., Franklin Becker) helps Novo Nordisk blend “celebrity” testimonial appeal with grounded patient representation.
In marketing discussions, she is one of the “ordinary” people elevated to branded spokesperson status.
Fierce Pharma
Thus, her role is dual: she is both subject (someone living with diabetes) and object (a marketing instrument) in the campaign.
What do we really know — and what remains unknown?
Ozempic TV Spot, ‘Testimonials: Maria’
Because Maria is a promotional figure, there is a mix of disclosed and undisclosed information. Here’s an inventory of what can be known — and what is not:
What we do know:
Maria is publicly billed as a paid spokesperson for Novo Nordisk in this campaign, thus not just a random patient sharing their experience for free.
She identifies as having type 2 diabetes and taking Ozempic (semaglutide) as part of her regimen.
She is described as an entrepreneur and salon owner, balancing her business role and health.
Her testimonial claims include lowering her A1C and managing weight (or having weight considerations).
Her story is leveraged as part of a strategic narrative to humanize the product and make it more relatable for audiences with type 2 diabetes.
What remains unknown or cautious to assume:
We do not have independent verification of her clinical results (e.g. how much her A1C improved, weight loss amounts, duration). The information comes from branded sources.
It is not clear how typical or exceptional her results are relative to average outcomes on Ozempic — she is a promotional example, so selection bias is likely.
Her full medical history beyond what is shared in the commercials isn’t publicly documented (co-morbidities, prior medications, lifestyle changes).
We do not know whether her narrative is fully authentic or if it was shaped or scripted (as is often standard in ad campaigns).
Her identity outside the campaign (e.g. demographics, family background) is kept relatively private, likely for privacy and legal reasons.
Thus, while she is presented as a real person, she is also curated — which is common in pharmaceutical marketing.
How audiences interpret Maria’s presence — benefits and critiques
Maria’s presence in the Ozempic campaign functions in several ways — some strengths, some risks — from a marketing and public perception perspective.
Potential strengths:
Emotional resonance
Seeing a person talk credibly about their struggles (managing diabetes) helps viewers feel seen and understood. It humanizes medical messaging.
Relatability
Maria is positioned as someone with a “normal life” (business, family, daily responsibilities), so audiences may feel “if she can do it, maybe I can too.”
Credibility via “real voice”
A named individual with details (entrepreneur, salon owner) seems more trustworthy than an anonymous narrator. It suggests authenticity.
Narrative persuasion
Stories influence attitudes more effectively than facts alone. Maria’s story helps embed the medical claims in a narrative context, making them more memorable.
Differentiation in a crowded market
Many drug commercials list statistics; a testimonial face like Maria helps Ozempic stand out in consumers’ minds.
Potential critiques or caveats:
Selective storytelling
Because she is a promotional figure, the narrative will likely emphasize successes and downplay challenges or side effects. Viewers may apply her experience too optimistically to themselves.
Conflict of interest / commercial bias
As a paid spokesperson, her story is part of marketing, so full disclosure of benefits vs risks may be constrained by regulatory compliance.
Overgeneralization risk
Audiences might assume her results apply universally, when in reality individual responses to a drug vary.
Emphasis on weight/appearance
Some medical ads featuring GLP-1 drugs face criticism for overweighting weight loss narratives; Maria’s portrayal touches on both A1C and weight. Critics could argue that emphasis on weight might overshadow the core function (glucose control).
Opacity of medical data
Without transparent clinical data, viewers must trust the branded message. That trust may be influenced by skepticism toward pharmaceutical advertising.
Overall, Maria’s presence is a powerful branding device, but it comes with complexities inherent in medical marketing.
Why Maria (and voices like her) matter in modern pharma ads
Ozempic TV Commercials
The trend of embedding patient stories in pharmaceutical marketing has grown significantly. Rather than relying solely on data tables or voiceover disclaimers, companies increasingly use “real people” to lend narrative weight to treatment claims. Maria is a part of this evolution.
This model responds to consumer preferences: people are more persuaded by narratives than dry facts. Using a named individual with a face, context, and “before vs after” framing gives the message more emotional pull. In conditions like type 2 diabetes, which many people experience in daily life, identity and narrative matter deeply.
Additionally, regulatory constraints require balancing claims with safety disclosures; voices like Maria help carry that balance by making the messaging more digestible and less technical. Yet they also allow the brand to steer the narrative — what to highlight, what to omit, what emotional tone to strike.
In sum, Maria functions as a bridge: between medical evidence and human experience; between brand and patient; between marketing claim and lived reality. While not a neutral or unmediated voice, her presence reflects modern pharma’s strategy to align scientific messaging with storytelling.
Conclusion
So — who is Maria in the Ozempic commercial? She is a paid spokesperson for Novo Nordisk’s “My Ozempic Era” campaign, presented as a salon-owning entrepreneur living with type 2 diabetes, sharing her journey of taking Ozempic, lowering A1C, and maintaining confidence in her life. While much of what we see is drawn from branded storytelling, Maria is not merely fictional — she is part of the company’s effort to humanize medical messaging, to show that real people balance disease management with life ambitions.
Acting Magazine Newsletters
Never miss out on the best from Acting Magazine.